An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

Inclusion Criteria: (list is not all inclusive)

• Subject has given written informed consent and privacy authorization prior toparticipation in the study.

• Subject has completed the Treatment Period of Study SEP361-308.

• Subject has not taken any psychotropic medication other than the study drug,pre-switch antipsychotic and protocol-allowed medications during Study SEP361-308.

• Female subject must have a negative rapid urine pregnancy test at the End ofTreatment (EOT) Visit of Study SEP361-308.

Exclusion Criteria: (list is not all inclusive)

• Subject is suicidal based on the Columbia - Suicide Severity Rating Scale (C-SSRS)assessment at the End of Treatment (EOT) Visit of Study SEP361-308.

• Subject has a clinically significant abnormality including physical examination,vital signs, or ECG finding at the End of Treatment (EOT) Visit of Study SEP361-308.

• Subject has a positive rapid urine drug screen at the EOT Visit of Study SEP361-308.

• Female subject is pregnant or lactating.